Cervical cancer is preventable and curable if detected early and treated promptly. As the fourth most common cancer in women worldwide, it now faces a powerful global adversary: the World Health Organization (WHO).
On November 17, 2020, 194 countries committed under WHO leadership to combat cervical cancer. This groundbreaking global strategy—the first aimed at eliminating a cancer—focuses on three pillars: vaccination, screening, and treatment.
“The enormous burden of cervical cancer mortality stems from decades of global health neglect. But we can rewrite this story,” said WHO Assistant Director-General Dr. Princess Nothemba Simelela.
Without intervention, WHO projects cervical cancer cases rising from 570,000 to 700,000 annually by 2030, with deaths increasing from 310,000 to 400,000. Primarily caused by the human papillomavirus (HPV), this disease demands urgent action.
While vaccination, screening, and treatment are standard in high-income countries, access remains limited elsewhere, often due to vaccine costs.
To curb cervical cancer, WHO sets three 2030 targets:
Achieving these goals by 2030 could reduce new cases by over 40% and prevent 5 million deaths by 2050, putting all countries on a path to elimination, per WHO.
The COVID-19 pandemic poses challenges by disrupting services, yet “we can make history to ensure a future without cervical cancer,” Dr. Simelela affirmed.
The most effective prevention combines regular Pap smears with HPV vaccination.
Cervical cancer often develops silently, underscoring the need for routine screening. Symptoms like intermenstrual or postmenopausal bleeding warrant immediate attention.
Diagnosis starts with a Pap smear by a gynecologist or primary care physician, collecting cells for lab analysis of abnormalities. Performed outside menstruation, a positive result prompts biopsy, conization, or imaging (ultrasound, CT, MRI) to stage the cancer.
